Wrapmanager Inc Immuno Gen, Inc. Transaction History

Wrapmanager Inc

$382 Million
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 07, 2022	SELL	$4.75 - $7.5 $47,704 - $75,322	-10,043 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$5.02 - $6.59 $1,255 - $1,647	-250 Reduced 2.43%	10,043 $57,000
Q2 2021 Aug 04, 2021	BUY	$5.79 - $8.6 $451 - $670	78 Added 0.76%	10,293 $68,000
Q1 2021 May 10, 2021	SELL	$6.5 - $10.53 $942 - $1,526	-145 Reduced 1.4%	10,215 $83,000
Q4 2020 Feb 08, 2021	SELL	$3.7 - $7.66 $1,594 - $3,301	-431 Reduced 3.99%	10,360 $67,000
Q3 2020 Nov 12, 2020	SELL	$3.45 - $4.89 $1,169 - $1,657	-339 Reduced 3.05%	10,791 $39,000
Q2 2020 Aug 11, 2020	SELL	$3.32 - $5.34 $3,827 - $6,157	-1,153 Reduced 9.39%	11,130 $51,000
Q1 2020 May 08, 2020	SELL	$2.12 - $6.8 $2,448 - $7,854	-1,155 Reduced 8.6%	12,283 $42,000
Q4 2019 Feb 11, 2020	SELL	$2.25 - $5.8 $4,855 - $12,516	-2,158 Reduced 13.84%	13,438 $69,000
Q3 2019 Nov 12, 2019	SELL	$2.22 - $3.39 $894 - $1,366	-403 Reduced 2.52%	15,596 $38,000
Q2 2019 Jul 31, 2019	BUY	$1.8 - $3.3 $532 - $976	296 Added 1.88%	15,999 $35,000
Q1 2019 May 06, 2019	BUY	$2.41 - $5.91 $571 - $1,400	237 Added 1.53%	15,703 $43,000
Q4 2018 Feb 13, 2019	SELL	$3.94 - $9.7 $3,739 - $9,205	-949 Reduced 5.78%	15,466 $74,000
Q3 2018 Nov 13, 2018	BUY	$8.6 - $11.26 $928 - $1,216	108 Added 0.66%	16,415 $155,000
Q2 2018 Aug 03, 2018	SELL	$9.52 - $12.15 $8,434 - $10,764	-886 Reduced 5.15%	16,307 $159,000
Q1 2018 May 03, 2018	BUY	$6.7 - $12.95 $11,999 - $23,193	1,791 Added 11.63%	17,193 $181,000
Q4 2017 Feb 02, 2018	SELL	$5.07 - $7.92 $116 - $182	-23 Reduced 0.15%	15,402 $99,000
Q3 2017 Nov 03, 2017	BUY	$5.4 - $8.47 $83,295 - $130,649	15,425	15,425 $118,000

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wrapmanager Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wrapmanager Inc with notifications on news.

Account